Location via proxy:   [ UP ]  
[Report a bug]   [Manage cookies]                
Scribd Logo
Upload

Welcome to Scribd!

  • 36 views

    Rtog 1308

    Uploaded by

    api-632827798
    The RTOG 1308 clinical trial aims to compare overall survival rates for patients with inoperable stage II-IIIB non-small cell lung cancer (NSCLC) receiving either photon or proton chemoradiotherapy. Patients receive 70 Gy of radiation along with concurrent chemotherapy. The trial seeks to evaluate if proton therapy results in less toxicity to organs at risk and improved pulmonary function, quality of life, and cost effectiveness compared to photon therapy. It is hypothesized that patients receiving proton therapy will have less severe symptoms at their 6-month follow up. The trial completion is projected for December 2024.

    Copyright:

    © All Rights Reserved
    Download as PDF, TXT or read online from Scribd

    Rtog 1308

    Uploaded by

    api-632827798
    36 views2 pages
    The RTOG 1308 clinical trial aims to compare overall survival rates for patients with inoperable stage II-IIIB non-small cell lung cancer (NSCLC) receiving either photon or proton chemoradiotherapy. Patients receive 70 Gy of radiation along with concurrent chemotherapy. The trial seeks to evaluate if proton therapy results in less toxicity to organs at risk and improved pulmonary function, quality of life, and cost effectiveness compared to photon therapy. It is hypothesized that patients receiving proton therapy will have less severe symptoms at their 6-month follow up. The trial completion is projected for December 2024.

    Original Title

    rtog 1308

    Copyright

    © © All Rights Reserved

    Available Formats

    PDF, TXT or read online from Scribd

    Did you find this document useful?

    Is this content inappropriate?

    The RTOG 1308 clinical trial aims to compare overall survival rates for patients with inoperable stage II-IIIB non-small cell lung cancer (NSCLC) receiving either photon or proton chemoradiotherapy. Patients receive 70 Gy of radiation along with concurrent chemotherapy. The trial seeks to evaluate if proton therapy results in less toxicity to organs at risk and improved pulmonary function, quality of life, and cost effectiveness compared to photon therapy. It is hypothesized that patients receiving proton therapy will have less severe symptoms at their 6-month follow up. The trial completion is projected for December 2024.

    Copyright:

    © All Rights Reserved
    Download as PDF, TXT or read online from Scribd
    Download as pdf or txt
    36 views2 pages

    Rtog 1308

    Uploaded by

    api-632827798
    The RTOG 1308 clinical trial aims to compare overall survival rates for patients with inoperable stage II-IIIB non-small cell lung cancer (NSCLC) receiving either photon or proton chemoradiotherapy. Patients receive 70 Gy of radiation along with concurrent chemotherapy. The trial seeks to evaluate if proton therapy results in less toxicity to organs at risk and improved pulmonary function, quality of life, and cost effectiveness compared to photon therapy. It is hypothesized that patients receiving proton therapy will have less severe symptoms at their 6-month follow up. The trial completion is projected for December 2024.

    Copyright:

    © All Rights Reserved
    Download as PDF, TXT or read online from Scribd
    Download as pdf or txt
    of 2

    RTOG 1308: Phase III Randomized Trial Comparing Overall Survival After Photon Versus

    Proton Chemoradiotherapy for Inoperable Stage II-IIIB NSCLC (Non-Small Cell Lung Cancer)
    The RTOG 1308 clinical trial was set in place to improve the mean survival for patients
    affected by non-small cell lung cancer in both patient groups treated with photons and proton
    therapy. This trial is currently being held through the NRG. One of the main factors for this trial
    being that the prescribed dose would be 70 Gy based on previous clinical trials and their results
    to help lower toxicities to various organs at risk (OAR) and increase the average survival time
    for patients.1 Other secondary objectives include evaluating pulmonary function, quality of life,
    and cost effectiveness.2 Patients receive concurrent chemotherapy while radiation treatments are
    ongoing. Patients eligible for this clinical trial must be diagnosed with stage II-IIIB NSCLC.
    Patients also had to be considered ineligible for surgery and could not have received prior
    radiotherapy or chemotherapy. Following stratification, patients are randomized into two
    different study arms.1 It is hypothesized that the patients in the proton arm will show less severe
    symptoms at the 6-month follow-up.

    There are little treatment options available for patients who are affected by NSCLC, thus
    this study also aims to explore the potential benefits of radiation therapy at these dose levels. As
    proton centers are not available at every clinical site, with promising results this could encourage
    the use of photon therapy as a form of treatment for NSCLC.2 The concurrent chemotherapy
    regimen will be determined by the physician prior to the start of radiation treatments. Some of
    the technical factors involving the treatment planning include only using energies of 6-10 MeV
    with a total dose of 70 Gy delivered over 35 fractions.1 Proton plans are permitted to use energies
    that lead to adequate tissue penetration. Simulation requires motion management in some form.
    This can include utilizing a 4D CT scan or other respiratory gating options.1 The target volumes
    must include a: GTV, IGTV, CTV, ITV and a PTV. Primary planning objectives regarding tumor
    volume coverage is for 95% of the PTV to receive a minimum of 95% of the prescribed dose.1 If
    this criterion is not able to be met, there are slight variations acceptable. The following OAR
    must be delineated in the treatment plan: Spinal canal, lungs- GTV, bilateral lungs, esophagus,
    brachial plexi, heart, liver, and bilateral kidneys.1 There is currently no published data on the trial
    as it is still ongoing. The projected completion date is in December 2024.
    References:

    1. NRG. RTOG 1308: Phase III Randomized Trial Comparing Overall Survival After
    Photon Versus Proton Chemoradiotherapy for Inoperable Stage II-IIIB NSCLC. National
    Library of Medicine.
    2. NIH. History of Changes for Study: NCT01993810 Comparing Photon Therapy to Proton
    Therapy to Treat Patients with Lung Cancer. History of changes for study:
    NCT01993810. Accessed July 18, 2023.
    https://classic.clinicaltrials.gov/ct2/history/NCT01993810?V_13=View#StudyPageTop.

    You might also like